Ad
related to: pamrevlumab orphan drug information
Search results
Results from the WOW.Com Content Network
Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein. [2] This drug was developed by FibroGen, Inc. [3]
Garadacimab is an experimental human monoclonal antibody under investigation for the treatment of hereditary angioedema. [1] Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.
Orphan drug status, which is given to drugs meant for the treatment of rare diseases, offers drug developers a path to faster approval and enhanced market exclusivity. So let's look at a small ...
The U.S. Food and Drug Administration (FDA) granted orphan drug designations in 2010 and 2020, [9] [10] and breakthrough therapy designation in 2016, on the basis of preliminary data from the phase II trial. [11]
BioMarin Pharmaceuticals (NAS: BMRN) keeps chugging along, pushing its orphan drug pipeline forward. Yesterday, the biotech announced data from two trials, giving the company confidence to move ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
The US Food and Drug Administration (FDA) granted the application for sutimlimab orphan drug, [3] [12] breakthrough therapy, [3] and priority review designations. [ 3 ] Society and culture
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Ad
related to: pamrevlumab orphan drug information